Registry for outcomes of radiation therapy in cancer patients
Official title: Evaluation Tracking Project: A Prospective Chart Review of Patients Treated With Radiation Therapy
Run by Proton Collaborative Group · NCT01255748 · Data updated 2026-11-12
This study is collecting information from cancer patients receiving different types of radiation therapy to see how well these treatments work and how safe they are.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 50000 (estimated) |
| Sponsor | Proton Collaborative Group Research network |
| Drugs / interventions | radiation |
| Locations | 29 sites (Scottsdale, Arizona and 28 other locations) |
| Status | Recruiting |
| Started | June 2009 |
| Main results expected | June 2039 |
| Registry record updated | September 29, 2026 |
| Trial ID | NCT01255748 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients who are scheduled to receive radiation therapy for their cancer treatment.
✕Probably not a fit
Patients who are not undergoing radiation therapy or who cannot provide informed consent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to collect and analyze data from patients undergoing various forms of radiation therapy, including proton therapy, photon therapy, stereotactic radiosurgery (SRS), and brachytherapy. By gathering information on treatment outcomes, the study seeks to enhance understanding of the effectiveness and safety of these radiation modalities in treating neoplasms. Participants will be required to provide informed consent and will be monitored throughout their treatment process.
Why it matters
Potential benefit: If successful, this study could improve treatment strategies and outcomes for cancer patients receiving radiation therapy.
How similar studies have gone: Other studies have shown success in analyzing radiation therapy outcomes, making this approach a continuation of established research.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Planned treatment with radiation therapy * Ability to understand and sign IRB approved consent
Where it's running
-
Mayo Clinic
Scottsdale, Arizona, United States Recruiting -
Proton Center of Arkansas
Little Rock, Arkansas, United States Recruiting -
California Protons Cancer Therapy Center
San Diego, California, United States Recruiting -
South Florida Proton Therapy Institute
Delray Beach, Florida, United States Recruiting -
Southwest Florida Proton Center
Fort Myers, Florida, United States Recruiting -
Ackerman Cancer Center
Jacksonville, Florida, United States Recruiting
Show 23 more locations
-
Dwoskin Proton Therapy Center
Miami, Florida, United States Recruiting -
Miami Cancer Institute
Miami, Florida, United States Recruiting -
Orlando Health Cancer Institute
Orlando, Florida, United States Recruiting -
Emory Proton Therapy Center
Atlanta, Georgia, United States Recruiting -
OSF HealthCare Cancer Institute
Peoria, Illinois, United States Recruiting -
Northwestern Medicine Chicago Proton Center
Warrenville, Illinois, United States Recruiting -
University of Kansas Proton Therapy Center
Kansas City, Kansas, United States Recruiting -
Kansas City Proton Institute
Overland Park, Kansas, United States Recruiting -
Willis-Knighton Cancer and Proton Therapy Center
Shreveport, Louisiana, United States Recruiting -
Maryland Proton Treatment Center
Baltimore, Maryland, United States Recruiting -
McLaren Proton Therapy Center
Flint, Michigan, United States Recruiting -
Mercy David C. Pratt Cancer Center
St Louis, Missouri, United States Recruiting -
ProCure Proton Therapy Center
Somerset, New Jersey, United States Recruiting -
New York Proton Center
New York, New York, United States Recruiting -
Atrium Health Levine Cancer Proton & Advanced Radiation Center
Charlotte, North Carolina, United States Recruiting -
University of Cincinnati Medical Center
Cincinnati, Ohio, United States Recruiting -
Oklahoma Proton Center
Oklahoma City, Oklahoma, United States Recruiting -
Tennessee Oncology Proton Center
Franklin, Tennessee, United States Recruiting -
Thompson Proton Center
Knoxville, Tennessee, United States Recruiting -
Texas Center for Proton Therapy
Irving, Texas, United States Recruiting -
Inova Schar Cancer Institute
Fairfax, Virginia, United States Recruiting -
Hampton University Proton Therapy Institute
Hampton, Virginia, United States Recruiting -
University of Washington
Seattle, Washington, United States Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HR20013 for preventing nausea and vomiting in cancer patients receiving chemotherapy
This real-world study tests whether HR20013 helps prevent nausea and vomiting in adults with cancer who are getting chemotherapy.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
-
Ready for Safe Cancer Treatment (RESET): A comprehensive perioperative program for surgical patients
The RESET program tests a structured, multidisciplinary perioperative plan to improve safety and recovery for adults having planned cancer surgery and older adults having planned non cancer-related surgery.
-
How environment and biology together predict health, aging, and death
Researchers are following adults to see how living conditions and biology together relate to aging and life expectancy, by linking personal health data with environmental and social information over time.
-
Metastatic liver cancer patient registry from multiple Chinese centers
This is a registry that collects real-world data on adults with liver metastases to understand patterns and prognosis and to support future research.
-
TriAdeno and N-803 vaccine in early prostate cancer on active surveillance
A vaccine combo called TriAdeno plus the N-803 drug is being tested to see if it can help slow or stop growth in men with early-stage, low- to intermediate-risk prostate cancer who are being watched rather than treated right away.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.